Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults - GlobeNewswire

Submitted by Anonymous (not verified) on Thu, 10/20/2022 - 11:00

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults GlobeNewswire

Log in to post comments